<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="758">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04355026</url>
  </required_header>
  <id_info>
    <org_study_id>SBCebromhexinCovid-19</org_study_id>
    <nct_id>NCT04355026</nct_id>
  </id_info>
  <brief_title>Use of Bromhexine and Hydroxychloroquine for Treatment of COVID-19 Pneumonia</brief_title>
  <official_title>Use of Bromhexine and Hydroxychloroquine for Treatment of COVID-19 Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>General and Teaching Hospital Celje</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>General and Teaching Hospital Celje</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the current situation it is of great importance to discover a safe, cost-effective and
      available treatment strategy in order to limit the rapidly spreading SARS-Cov-2. Recent
      studies have shown that hydroxychloroquine could have a role in the treatment of infected
      patients. It is however not very likely that hydroxychloroquine alone could be adequate for
      treatment of Covid-19 disease. Effective therapy that prevents the virus entrance should
      contain at least TMPRSS2 inhibitor or a competitive inhibitor of viral ACE 2 binding. The use
      of bromhexine at the dose adequate to selectively inhibit the TMPRSS2, resulting in
      preventing of viral entrance via TMPRSS2-specific pathway, coud be an effective treatment of
      Covid-19. In our study we would like to explore the therapeutic potential of bromhexin and
      hydroxychloroquine in Covid-19 patients.

      Hypothesis

        1. Combined treatment with bromhexin and hydroxychloroquine shortens the course of disease
           in hospitalized Covid-19 patients compared to hydroxychloroquine alone.

        2. Combined treatment with bromhexin and hydroxychloroquine lowers the incidence of
           secundary pulmonary infections in hospitalized Covid-19 patients compared to
           hydroxychloroquine alone.

        3. Combined treatment with bromhexin and hydroxychloroquine decreases the need for ICU
           admission in hospitalized Covid-19 patients compared to hydroxychloroquine alone.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">April 10, 2020</start_date>
  <completion_date type="Anticipated">July 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of hospitalization</measure>
    <time_frame>through study completion, an average of 6 months</time_frame>
    <description>number of days the patient is treated in the hospital</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of disease</measure>
    <time_frame>through study completion, an average of 6 months</time_frame>
    <description>Number of days from the onset of symptoms to hospital discharge</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hospital-aquired pneumonia</measure>
    <time_frame>through study completion, an average of 6 months</time_frame>
    <description>Incidence of HAP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU stay duration</measure>
    <time_frame>through study completion, an average of 6 months</time_frame>
    <description>Number of days spent in the ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygene therapy duration</measure>
    <time_frame>through study completion, an average of 6 months</time_frame>
    <description>number of days on oxygene therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mechanical ventilatory support duration</measure>
    <time_frame>through study completion, an average of 6 months</time_frame>
    <description>Number of hours on mechanical ventilation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Covid-19</condition>
  <arm_group>
    <arm_group_label>hydroxychloroquine and bromhexine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bromhexine 16 mg TID + hydroxychloroquine 200 mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hydroxychloroquine alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>hydroxychloroquine 200 mg BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bromhexine Oral Tablet and/or hydroxychloroquine tablet</intervention_name>
    <description>bromhexine 16 mg TID hydroxychloroquine 200 mg BID</description>
    <arm_group_label>hydroxychloroquine alone</arm_group_label>
    <arm_group_label>hydroxychloroquine and bromhexine</arm_group_label>
    <other_name>hydroxychloroquine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt; 18 years,

          -  confirmed infection (positive PCR from nasopharyngeal swab),

          -  fullfilled hospital admission criteria

        Exclusion Criteria:

          -  pregnancy,

          -  known allergy for bromhexine or hydroxychloroquine,

          -  epilepsy,

          -  prolonged QTc interval,

          -  Child C liver disease,

          -  dementia,

          -  psychoorganic syndrome,

          -  terminal chronic disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Miha Mežnar</last_name>
    <phone>+386 3 4233419</phone>
    <email>meznar.miha@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>matej Podbregar</last_name>
    <phone>+386 3 4233418</phone>
    <email>matej.podbregar@sb-celje.si</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>SB Celje</name>
      <address>
        <city>Celje</city>
        <zip>3000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miha Mežnar</last_name>
      <phone>+386 3 4233419</phone>
      <email>meznar.miha@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Matej Podbregar</last_name>
      <phone>+386 3 4233419</phone>
      <email>matej.podbregar@sb-celje.si</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Slovenia</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 15, 2020</study_first_submitted>
  <study_first_submitted_qc>April 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2020</study_first_posted>
  <last_update_submitted>April 18, 2020</last_update_submitted>
  <last_update_submitted_qc>April 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxychloroquine</mesh_term>
    <mesh_term>Bromhexine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

